Cipla Q2 FY26 Earnings Call Analysis

1. Financial Summary:

• Consolidated Revenue: INR7,589 crores (all-time high quarterly revenue), up 8% YoY.
• EBITDA (excluding other income): Margin of 25%.
• PAT: INR1,351 crores, representing 17.8% of sales.
• Gross Margin: 67%, impacted by product mix and R&D material purchases.
• R&D Investment: INR539 crores, 7.1% of revenue.
• Net Cash Balance: INR9,901 crores.

2. Geographic Revenue Breakdown:

• US Business:
  • Revenue of $233 million.
  • Number one player in the U.S. albuterol MDI market with a 22% market share.
  • Lanreotide market share at 22%.
  • Launched filgrastim (biosimilar).
  • Generic drug approval for glucagon and tentative approval for liraglutide (partnered).
  • Generic Revlimid contribution expected to be small in Q3 FY26.
  • Base business (excluding generic Revlimid) expected to continue growth in Q3 over Q2.
• India (Domestic Formulations):
  • 7% YoY growth.
  • Branded prescriptions business grew at 8%, with key therapies showing double-digit growth (anti-diabetes 10%, cardiac 13%, urology 17%, dermatology 18%).
  • Chronic mix strengthened to 61.8%.
  • Foracort ranked number one brand in IPM.
  • Added four new brands to the INR100 crores+ club (total 29).
  • Cipla is the largest pharma company in terms of volume (2 billion+ unit sales in IPM).
  • Entering obesity care with Yurpeak (tirzepatide).
• Europe & Emerging Markets (EMEU):
  • Strongest quarterly revenue to date at USD 110 million, up 15% YoY.
  • One Africa business recorded a growth of 5% YoY in USD terms, with South Africa growing at 6% in ZAR terms.
  • Private market in South Africa grew at 6.2%, outperforming the market growth of 4.7%.

3. R&D and Pipeline:

• R&D expenses: 7.1% of revenue (INR539 crores). Expected to be 0.5% higher than planned for the full year.
• Key Pipeline Updates:
  • US: Expects to launch four major respiratory assets by calendar year '26, including generic Advair in Q4 '26.
  • Three peptide assets, including liraglutide, are also in the pipeline.
  • Three of the four respiratory assets are filed from U.S. facilities.
  • India: Launching Yurpeak (tirzepatide) for obesity care, Doloneuron and Zolsoma (CNS), XTIKTR (urology), Elbicip (gastroenterology), Aprela (dermatology), Rizontem and Tedispan (anti-infectives).
• Filings and Approvals:
  • Received generic drug approval for glucagon and tentative approval for liraglutide (partnered).

4. Regulatory & Plant Updates:

• USFDA inspected the Bommasandra, Bengaluru facility in Q1 FY26 and qualified it as VAI.
• Reinspection of the Indore facility expected this year or early next year.
• Kemwell facility pre-approval inspection recently.

5. Guidance, Outlook & Targets:

• Management Commentary:
  • Focus on execution to regain growth momentum in India.
  • Enhance commercial execution and accelerate new product introductions in North America.
  • Margin expansion in South Africa.
  • Top-line growth by deepening penetration in core markets in EMEU.
  • Increasing R&D spend to capitalize on pipeline opportunities. | Metric | Target Value | Timeframe | |---|---|---| | EBITDA Margin | 22.75% - 24% | FY26 (excluding Yurpeak) | | US Sales | $1 billion | Next Year (dependent on approval timelines) | | US Launches | Four major respiratory assets, including generic Advair in Q4 '26 | Calendar Year '26 |